U.S. Personal Products Stock News

CRISPR Therapeutics (CRSP) has moved back into focus after reporting strong commercial traction for its approved gene therapy CASGEVY, along with the completion of a US$600 million convertible note offering that lifts pro forma cash above US$2.5b. See our latest analysis for CRISPR Therapeutics. Despite recent news on CASGEVY and the new convertible notes, the share price has cooled, with a 30-day share price return of an 11.74% decline and a 1-year total shareholder return of 13.99%,...

Savara Inc. recently reported a US$32.24 million net loss for the fourth quarter of 2025, while also signing a new six-year headquarters lease in Yardley, Pennsylvania starting July 2026 with aggregate base rent of about US$1.78 million and five months of rent abatement. At the same time, the company advanced its lead therapy MOLBREEVI for autoimmune PAP, with the FDA confirming no advisory committee is planned and marketing applications progressing in Europe and the U.K., underscoring how a...

Kontoor Brands' Lee, part of NYSE:KTB, has launched an exclusive collaboration with J.Crew. The collection reimagines Lee's legacy denim styles with a fresh take on American classics. The capsule uses premium materials and is available for men, women, and kids through Lee.com and J.Crew. This is the first Lee collaboration spanning all age groups on Lee.com, signaling a shift toward a more premium, fashion forward positioning. Kontoor Brands, the owner of Lee and Wrangler, operates in a...

Earlier this week, Lindblad Expeditions reported a 23.3% year-on-year revenue increase and a strong EBITDA beat, but significantly missed analysts’ earnings-per-share estimates. This combination of robust top-line growth and weaker bottom-line performance has raised questions about how effectively the company is converting demand into sustainable profits. Next, we’ll explore how Lindblad’s strong revenue beat but weaker earnings performance could influence its investment narrative and future...

Valuation snapshot and recent performance Interface (TILE) has drawn investor attention after recent price moves, with the stock last closing at $25.15. Against this backdrop, some investors are reassessing the company’s valuation and recent return profile. See our latest analysis for Interface. The recent 1 month share price return of 25.04% and 7 day share price return of 9.06% may point to fading short term momentum. However, the 1 year total shareholder return of 27.59% and 3 year total...

Caterpillar (CAT) is back in focus after a roughly 10% decline over the past month, even though its return over the past 3 months remains positive. That gap is prompting fresh attention to its recent performance. See our latest analysis for Caterpillar. The recent 10% 1 month share price decline sits against a still strong backdrop, with a 19.5% 3 month share price return, 15.1% year to date share price return and a very large 5 year total shareholder return. Taken together, these figures...

Hycroft Mining Holding Corporation recently reported additional high-grade silver drill results from its 2025–2026 program at the Brimstone area of the Hycroft Mine in Nevada, confirming the silver system extends about 150 meters deeper, remains open laterally, and supports the company’s structural model for the high-grade zone. These results, alongside a very large 55% increase in measured and indicated gold and silver resources to 16.4 million ounces of gold and 562.6 million ounces of...

Gold producer Newmont (NEM) is back in focus after its shares dropped sharply alongside a steep fall in bullion prices, as rising Middle East tensions and expectations for prolonged higher US interest rates pressured the sector. See our latest analysis for Newmont. The latest drop comes on top of a 13.35% 7 day share price decline and an 18.89% 30 day share price decline, yet Newmont still has a 110.41% 1 year total shareholder return. This suggests that short term momentum has cooled after a...

If you are wondering whether Avantor's current share price reflects its true worth, the recent valuation checks offer some clear signals to unpack. The stock last closed at US$7.61, with returns of 3.7% decline over 7 days, 15.9% decline over 30 days, 33.6% decline year to date, and 53.3% decline over the past year, which can change how investors think about both risk and potential reward. Recent coverage has focused on Avantor's position in life sciences tools and services and how the...

Event context and recent stock performance Conagra Brands (CAG) has been under pressure recently, with the share price closing at US$15.40 and showing negative returns over the past week, month and past 3 months. Those shorter term moves sit alongside a negative 1 year total return of about 36% and a negative 3 year total return of about 50%, prompting investors to reassess how the packaged food group’s fundamentals and valuation line up. See our latest analysis for Conagra Brands. Recent...

Taysha Gene Therapies (TSHA) has wrapped up FY 2025 with Q4 revenue of US$5.5 million and a basic EPS loss of US$0.08, alongside a full year trailing revenue base of US$9.8 million and a trailing EPS loss of US$0.34 that keeps profitability firmly out of reach for now. Over recent quarters, the company has seen revenue move between US$0 and US$5.5 million while quarterly basic EPS losses ranged from about US$0.08 to US$0.10. This sets a clear picture of a business still in heavy investment...

Jefferies’ recent upgrade of Simply Good Foods (SMPL), highlighting its focus on protein-centric products and the role of the Quest brand in key categories, has put fresh attention on the stock. See our latest analysis for Simply Good Foods. The Jefferies upgrade and upcoming Q2 FY2026 results come after a period where the 1-year total shareholder return of Simply Good Foods is down 56.24%, and the 90-day share price return of negative 25.76% contrasts with a recent 1-day gain of 1.60%,...

GE Vernova (GEV) has become a focal point after management refreshed its growth outlook through 2028, linking higher margin and cash flow expectations to a growing backlog, robust orders, and exposure to data centers and nuclear power. See our latest analysis for GE Vernova. That refreshed outlook adds to very strong recent performance, with the share price delivering a 90 day share price return of 33.29% and a 1 year total shareholder return of 161.26%, which indicates rising growth...

Rayonier (RYN) has been drawing attention after a period of weaker share performance, with the stock showing negative returns over the past month, past 3 months and year, even as revenue and net income figures remain available. See our latest analysis for Rayonier. At a share price of US$19.90, Rayonier has seen a 15.86% 1 month share price decline and a 7.91% year to date share price decline. The 1 year total shareholder return is down 21.63%, which points to fading momentum as the market...

Crescent Energy (CRGY) has come into focus after increasing the size of a $600 million convertible senior notes offering at a 2.75% interest rate, as management emphasizes debt maturity extension and balance sheet strengthening. See our latest analysis for Crescent Energy. The recent upsized convertible notes issue and focus on deleveraging come against a backdrop of strong momentum. Crescent Energy’s 30 day share price return is 22.99% and its 90 day share price return is 52.17%, while the 1...

Earlier in March, RadNet, Inc. participated in Barclays’ Global Healthcare Conference and KeyBanc’s Healthcare Virtual Forum, where Executive Vice President and CFO Mark Stolper outlined the company’s plans across its outpatient imaging and digital health businesses. During these appearances, RadNet emphasized its push into radiology AI, highlighting the Gleamer acquisition as a key step in expanding its DeepHealth platform globally. We’ll now examine how RadNet’s AI-focused expansion,...

Constellation Brands, NYSE:STZ, has outlined new growth projects and marketing plans centered on its Pacifico beer brand as part of its 2027 strategy. The company is preparing targeted campaigns and new pack sizes around upcoming global events such as the World Cup, with an eye on volume recovery for Pacifico. Management has also indicated an adjustment to long term margin targets in response to shifting cost pressures and competition. For investors watching NYSE:STZ, the update comes with...

Escalating conflict in Iran has pushed Brent crude above US$100 per barrel. EOG Resources (EOG) is in focus as investors weigh how higher prices and improving analyst sentiment may influence its cash generation. See our latest analysis for EOG Resources. Those stronger oil prices and a string of supportive analyst updates have coincided with a sharp move in EOG, with a 15.9% 1 month share price return and a 36.2% 3 month share price return. The 5 year total shareholder return of 142.7% points...

Akso Health Group (AHG) recently hit a new 52 week high at US$2.10, alongside reported 75.6% revenue growth and a 30% total return over the past year, despite a thin 1% gross margin. See our latest analysis for Akso Health Group. The latest move to US$2.42 comes after a strong run, with an 84.7% 1 month share price return and a 51.3% year to date share price return. The 1 year total shareholder return of 92.1% and very large 3 year total shareholder return suggest momentum has been building...

Resolute Holdings Management (RHLD) has drawn fresh attention after recent trading left the stock with a 9% decline over the past month and a 24% decline over the past three months, sharpening focus on its valuation profile. See our latest analysis for Resolute Holdings Management. Despite the recent 30 day and 90 day share price returns of 8.6% and 24.6% declines, respectively, the 1 year total shareholder return of about 3.7x and the latest $164.17 share price point to fading short term...

Accelerant Holdings (ARX) closed FY 2025 with fourth quarter revenue of US$326.9 million and a basic EPS loss of US$0.0027, while the trailing twelve month figures showed revenue of US$912.9 million and a basic EPS loss of US$7.49. Over recent periods, the company has seen quarterly revenue move from US$181.2 million in Q4 2024 to US$163.5 million in Q1 2025, US$204.7 million in Q2 2025, US$217.8 million in Q3 2025 and US$326.9 million in Q4 2025, with EPS shifting from US$10.57 in Q4 2024 to...

Lucid Group (LCID) continues to draw attention from EV investors, with shares most recently closing at US$10.30. Recent returns include a single-day gain of 3.5% and a decline of 12.9% over the past three months. See our latest analysis for Lucid Group. The recent 3.5% one day share price return and 4.7% 7 day share price return contrast with a 12.9% 90 day share price decline and a 54.8% 1 year total shareholder return loss. This suggests momentum has been weak over the longer term. If...

FDA approval sets new context for Protagonist Therapeutics The recent U.S. FDA approval of ICOTYDE for moderate to severe plaque psoriasis is a major regulatory milestone for Protagonist Therapeutics (PTGX). This development is putting fresh attention on the company’s commercial potential and broader pipeline. See our latest analysis for Protagonist Therapeutics. The FDA approval has arrived after a strong run in the shares, with a 23.31% 1 month share price return and a 91.67% 1 year total...

Lands' End (LE) has rounded out FY 2026 with Q4 revenue of US$462.4 million and basic EPS of US$0.40, supported by net income of US$12.3 million. Over recent quarters, the company has seen revenue move from US$261.2 million in Q1 2026 to US$317.5 million in Q3 2026 before reaching US$462.4 million in Q4. Quarterly EPS shifted from a loss of US$0.27 in Q1 to a profit of US$0.40 in Q4. For investors, the focus now is on how sustainable these earnings are given the thin trailing net profit...